- Home
- LPTH vs REVBW Comparison
LPTH vs REVBW Comparison
Compare LPTH & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- REVBW
- Stock Information
- Founded
- LPTH 1985
- REVBW N/A
- Country
- LPTH United States
- REVBW United States
- Employees
- LPTH N/A
- REVBW 9
- Industry
- LPTH Semiconductors
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- REVBW Health Care
- Exchange
- LPTH Nasdaq
- REVBW Nasdaq
- Market Cap
- LPTH N/A
- REVBW N/A
- IPO Year
- LPTH 1996
- REVBW 2020
- Fundamental
- Price
- LPTH $1.50
- REVBW $0.01
- Analyst Decision
- LPTH Strong Buy
- REVBW
- Analyst Count
- LPTH 2
- REVBW 0
- Target Price
- LPTH $3.00
- REVBW N/A
- AVG Volume (30 Days)
- LPTH 54.0K
- REVBW N/A
- Earning Date
- LPTH 11-07-2024
- REVBW N/A
- Dividend Yield
- LPTH N/A
- REVBW N/A
- EPS Growth
- LPTH N/A
- REVBW N/A
- EPS
- LPTH N/A
- REVBW N/A
- Revenue
- LPTH $32,049,325.00
- REVBW N/A
- Revenue This Year
- LPTH $12.85
- REVBW N/A
- Revenue Next Year
- LPTH $16.37
- REVBW N/A
- P/E Ratio
- LPTH N/A
- REVBW N/A
- Revenue Growth
- LPTH N/A
- REVBW N/A
- 52 Week Low
- LPTH $1.04
- REVBW N/A
- 52 Week High
- LPTH $1.74
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- LPTH 45.86
- REVBW N/A
- Support Level
- LPTH $1.40
- REVBW N/A
- Resistance Level
- LPTH $1.59
- REVBW N/A
- Average True Range (ATR)
- LPTH 0.07
- REVBW 0.00
- MACD
- LPTH -0.02
- REVBW 0.00
- Stochastic Oscillator
- LPTH 43.48
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).